Table 1.

HLA class I and class II expression

AntibodyExtranodal DLCL*Nodal DLCL* % of cases
(n = 21)
Total
extranodal
vs nodal DLCL
Testicular % of cases (n = 28)CNS % of cases (n = 11)
+/−++/−++/−+P
HLA-A 61 29 11 55 18 27 10 33 57 0.008 
β2M 23 46 31 18 27 55 11 84 0.7 
TAP 26 33 41 30 40 30 91 0.02 
HLA-DR 61 29 11 46 18 36 10 85 0.004 
W6/32 62 38 75 25 25 13 62 0.4 
AntibodyExtranodal DLCL*Nodal DLCL* % of cases
(n = 21)
Total
extranodal
vs nodal DLCL
Testicular % of cases (n = 28)CNS % of cases (n = 11)
+/−++/−++/−+P
HLA-A 61 29 11 55 18 27 10 33 57 0.008 
β2M 23 46 31 18 27 55 11 84 0.7 
TAP 26 33 41 30 40 30 91 0.02 
HLA-DR 61 29 11 46 18 36 10 85 0.004 
W6/32 62 38 75 25 25 13 62 0.4 

HLA indicates human leukocyte antigen; DLCL, diffuse large B-cell lymphoma; CNS, central nervous system; β2M, β2-microglobulin.

*

 The − indicates no detectable staining of tumor cells compared with staining of internal control cells (respectively, T lymphocytes, macrophages, and dendritic cells for HLA class I, β2M, and TAP as well as macrophages and dendritic cells for class II) within each tumor. The +/− indicates weaker or heterogeneous staining of tumor cells compared with internal control cells.

 The P value was determined by using a two-sided Fisher exact test that compared the total loss of expression in extranodal (testis and CNS) and nodal DLCL.

 Frozen tissue sections of 13 testicular, 4 CNS, and 8 nodal DLCLs were stained for W6/32. One testicular and one CNS lymphoma were not interpretable for TAP. Two testicular and 3 nodal lymphomas were not interpretable for β2M.

or Create an Account

Close Modal
Close Modal